1221593-77-6

Basic information

• Product Name: 1-[5(S)-(N'-Pbf-guanidino)-2-(2,4,6-triisopropyl-benzenesulfonylamino)-pentanoyl]-piperidine-4-carboxylic acid ethyl ester
• Synonyms: 1-[5(S)-(N'-Pbf-guanidino)-2-(2,4,6-triisopropyl-benzenesulfonylamino)-pentanoyl]-piperidine-4-carboxylic acid ethyl ester
• CAS NO: 1221593-77-6
• Molecular Weight: 832.139
• Mol File: 1221593-77-6.mol
• Article Data: 9

Chemical Properties

• CAS DataBase Reference: 1-[5(S)-(N'-Pbf-guanidino)-2-(2,4,6-triisopropyl-benzenesulfonylamino)-pentanoyl]-piperidine-4-carboxylic acid ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1-[5(S)-(N'-Pbf-guanidino)-2-(2,4,6-triisopropyl-benzenesulfonylamino)-pentanoyl]-piperidine-4-carboxylic acid ethyl ester(1221593-77-6)
• EPA Substance Registry System: 1-[5(S)-(N'-Pbf-guanidino)-2-(2,4,6-triisopropyl-benzenesulfonylamino)-pentanoyl]-piperidine-4-carboxylic acid ethyl ester(1221593-77-6)

Safety Data

• Hazardous Substances Data: 1221593-77-6(Hazardous Substances Data)

Upstream product

• 186698-61-3 (S)-2-(tert-butoxycarbonylamino)-5-(3-(2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran-5-ylsulfonyl)guanidino)pentanoic acid 
• 6553-96-4 2,4,6-triisopropylphenylsulfonyl chloride 
• 1221593-74-3 1-[boc-Arg(Pbf)]piperidine-4-carboxylic acid ethyl ester 
• 200124-22-7 Boc-Arg-(Pbf)-OH 
• 1221593-74-3 (S,E)-ethyl 1-(2-(tert-butoxycarbonylamino)-5-(2-(2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran-5-ylsulfonyl)guanidino)pentanoyl)piperidine-4-carboxylate 
• 1345596-37-3 1-[Arg(Pbf)]-piperidine-4-carboxylic acid ethyl ester hydrochloride 
• 1126-09-6 4-carbethoxypiperidine 

Downstream Products

• 1276121-40-4 (S)-ethyl 1-(5-guanidino-2-(2,4,6-triisopropylphenylsulfonamido)pentanoyl)piperidine-4-carboxylate hydrochloride 
• 1221593-48-1 (S)-ethyl 1-(5-guanidino-2-(2,4,6-triisopropylphenylsulfonamido)pentanoyl)piperidine-4-carboxylate 

Relevant articles and documents

Pharmaceutical compositions with attenuated release of phenolic opioids

Pharmaceutical compositions and their methods of use are provided, where the pharmaceutical compositions comprise a phenolic opioid prodrug that provides enzymatically-controlled release of a phenolic opioid, and an enzyme inhibitor that interacts with th

COMPOSITIONS COMPRISING ENZYME-CLEAVABLE HYDROMORPHONE PRODRUG

The embodiments provide Compound PC-5, [2-((S)-2-malonylamino-6-amino-hexanoyl amino)-ethyl]-ethyl-carbamic acid hydromorphone ester, or acceptable salts, solvates, and hydrates thereof. The present disclosure also provides pharmaceutical compositions, and their methods of use, where the pharmaceutical compositions comprise a prodrug, Compound PC-5, that provides enzymatically-controlled release of hydromorphone, and, optionally, a trypsin inhibitor that interacts with the enzyme that mediates the enzymatically-controlled release of hydromorphone from the prodrug so as to attenuate enzymatic cleavage of the prodrug.

COMPOSITIONS COMPRISING ENZYME-CLEAVABLE OPIOID PRODRUGS AND INHIBITORS THEREOF

The present disclosure provides pharmaceutical compositions, and their methods of use, where the pharmaceutical compositions comprise a prodrug that provides enzymatically-controlled release of a drug and an enzyme inhibitor that interacts with the enzyme(s) that mediates the enzymatically-controlled release of the drug from the prodrug so as to attenuate enzymatic cleavage of the prodrug. The disclosure provides pharmaceutical compositions which comprise an enzyme inhibitor and a prodrug that contains an enzyme-cleavable moiety that, when cleaved, facilitates release of the drug.